Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Conversion Pharmacodynamic Study in Stable Renal Transplant Patients Receiving Tacrolimus Two Times a Day to a New Formulation of Tacrolimus - LCP Tacro - 1 Time a Day. (TACPKPD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02961608
Recruitment Status : Recruiting
First Posted : November 11, 2016
Last Update Posted : February 26, 2018
Sponsor:
Information provided by (Responsible Party):
NURIA LLOBERAS BLANCH, Hospital Universitari de Bellvitge

Brief Summary:

LCP-Tacro is an extended-release formulation of tacrolimus designed for once-daily dosing. Phase 1 studies demonstrated greater bioavailability than twice-daily tacrolimus capsules and no new safety concerns.

  • Stable kidney transplant patients can be safely converted from Adoport® twice-daily to LCP-Tacro®.
  • The greater bioavailability of LCP-Tacro after once-daily dosing results in similar (AUC) exposure, at a dose approximately 30% less, than the total daily dose of Adoport®.
  • LCP-Tacro provides a slow drug release and this results in flatter kinetics characterized by significantly lower peak-trough fluctuations.
  • CN is the major cellular target of the calcineurin inhibitors (CNIs) cyclosporine A (CsA) and tacrolimus. The ability of these drugs to inhibit CN activity is dependent on their binding to the respective immunophilins, cyclophilins A and B for CsA and FKBP12 for tacrolimus.
  • CN inhibition is a rate limiting phenomenon. Over concentrations of tacrolimus does not correlate with an increase in the CN activity.

Condition or disease Intervention/treatment Phase
Kidney Transplant; Complications Drug: Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®) Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 25 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Conversion Pharmacodynamic Study in Stable Renal Transplant Patients Receiving Tacrolimus Two Times a Day to a New Formulation of Tacrolimus - LCP Tacro - 1 Time a Day.
Study Start Date : May 2016
Estimated Primary Completion Date : September 2018
Estimated Study Completion Date : September 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Tacrolimus

Arm Intervention/treatment
Experimental: study group Drug: Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)
Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)




Primary Outcome Measures :
  1. Area under the curve (AUC) of CN activity [ Time Frame: Baseline and 35 days post conversion ]
    The main objective of this study is to compare the area under the curve (AUC) of CN activity after administration of a sustained release formulation (LCP- Tacro, Envarsus®) compared to an immediate release formulation (Prograf®) of TAC in renal transplant patients.


Secondary Outcome Measures :
  1. Area Under the curve 0-24 h of each TAC formulation [ Time Frame: Baseline and 35 days post conversion ]
    Pharmacokinetic study AUC 0-24 h of each TAC formulation 12h (Prograf®) and the new formulation of TAC every 24h (LCP- Tacro, Envarsus®).

  2. TAC trough concentrations for optimal inhibition of CN [ Time Frame: Baseline and 35 days post conversion ]
    Study PK / PD: relationship PK TAC (drug exposure) and PD (activity CN) of both formulations. Set TAC trough concentrations for optimal inhibition of CN.

  3. drug exposure according to CYP3A (CYP3A4 and CYP3A5 * 22 * 3) and ABCB1 (C3435T) polymorphism. [ Time Frame: Baseline and 35 days post conversion ]
    Analysis of drug exposure according to CYP3A (CYP3A4 and CYP3A5 * 22 * 3) and ABCB1 (C3435T) polymorphism.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult patients (≥ 18 years).

    • Receivers cadaveric renal graft or living donor with more than 6 months post-transplant evolution.
    • Patients receiving Prograf stable and stable TAC trough concentrations between 5-10ng / ml non-interrupted oral dose for at least 10 days (steady state conditions).
    • receiving concomitant immunosuppressive medication allowed: sodium or mycophenolate mofetil and corticosteroids.
    • Subjects must be willing to give their written informed consent to testing and be able to do consent. If a subject can not give written informed consent independently, you can do your legal representative instead.
    • Women of childbearing age must undergo a pregnancy test at the time of inclusion and accept the use of a medically acceptable method of contraception during the selection and receive medication as specified in the protocol.

Exclusion Criteria:

  • • Patients on dialysis or treatment of rejection after transplantation.

    • Patients treated with substances with potential interaction with TAC, particularly potent inhibitors of CYP3A4 (such as telaprevir, boceprevir, ritonavir, ketoconazole, voriconazole, itraconazole, telithromycin or clarithromycin) or inducers of CYP3A4 (such as rifampin or rifabutin).
    • Patients participating in another clinical trial or treated with any investigational drug within 30 days prior to inclusion.
    • Patients with liver disease.
    • The patient or donor with the current diagnosis or history of malignancy within the past 5 years except carcinoma nonmetastatic basal or squamous cell skin treated successfully.
    • pregnant or breast-feeding women and all women of childbearing age unless they use reliable contraception. A pregnancy test will be performed at screening and at the end of the study.
    • Receiver of any other organ transplanted kidney.
    • The recipients of bone marrow or stem cell transplant.
    • Recipients of a kidney from a donor ABO incompatible.
    • Patients with donor specific anti-HLA antibodies.
    • Recipients of a kidney with anticipated cold ischemia time of ≥ 24 hours.
    • Patients with concomitant uncontrolled infection, systemic infection in treatment, or any other unstable medical condition that could interfere with the study objectives.
    • Patients with severe diarrhea, vomiting, active peptic ulcer or gastrointestinal disorder that can affect the absorption of TAC.
    • Patients with white blood cell count ≤ 2.8 x 109 / L unless the absolute neutrophil count (ANC) is ≥ 1.0 x 109 / L
    • Patients with platelet count ≤ 50 x 109 / L
    • Patients with levels of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) exceeding> 3 times the upper limit of normal during the 30 days prior to the transplant procedure.
    • Patients with known hypersensitivity to TAC or any of the excipients in the formulation Envarsus®.
    • unable to swallow study medication patients.
    • Patients with any form of current substance abuse, psychiatric disorder or a condition that, in the investigator's opinion, may invalidate the communication with the investigator.
    • Patients who require a high intake of potassium or potassium-sparing diuretics.
    • Patients treated with substances with known nephrotoxic or neurotoxic effects.
    • positive for hepatitis C virus (HCV-RNA positive) and / or hepatitis B virus (HBV DNA or HBsAg positive) receivers.
    • positive for human immunodeficiency virus (HIV-Ab positive) receivers.
    • unable to understand the effects and risks of the study, who can not give informed consent in writing or unwilling to comply with the study protocol patients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02961608


Locations
Layout table for location information
Spain
Nephrology Department- Hospital Universitari Bellvtge Recruiting
L'Hospitalet de Llobregat, Barcelona, Spain, 08028
Contact: Nuria Lloberas, PhD    003493403586    nlloberas@ub.edu   
Principal Investigator: Nuria Lloberas, PhD         
Sponsors and Collaborators
Hospital Universitari de Bellvitge

Layout table for additonal information
Responsible Party: NURIA LLOBERAS BLANCH, PhD, Hospital Universitari de Bellvitge
ClinicalTrials.gov Identifier: NCT02961608     History of Changes
Other Study ID Numbers: TACPKPD
First Posted: November 11, 2016    Key Record Dates
Last Update Posted: February 26, 2018
Last Verified: February 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Tacrolimus
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action